This is a working overview of clinical endpoint, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-23 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Quantification of the peptide in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. This approach separates the analyte from matrix components and detects it by mass-to-charge transitions specific to the molecule. Immunoassays offer higher throughput but can cross-react with related peptides and metabolites, so mass spectrometric methods are preferred when structural confirmation is required. Method validation typically addresses accuracy, precision, selectivity, and stability under handling conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Enantiomeric impurities also impede RNA replication and chain elongation, processes central to both modern cellular processes like transcription and the RNA world hypothesis. As homochirality is ubiquitous in extant biology, a key question in origins of life and prebiotic chemistry research is how biological homochirality could have arisen from racemic mixtures of the simple chemical building blocks of life. Many mechanisms for the origin of homochirality have been proposed. Some of these models propose three distinct steps: a mirror-symmetry breaking mechanism to create a minute enantiomeric imbalance (enantiomeric excess or ee) from a racemic mixture, subsequent chiral amplification to achieve a larger ee or full homochirality (i.e., ee=100%), and finally chiral transmission/propagation to transfer chirality from one set of molecules to another. In addition, another important consideration is the environmental plausibility of proposed mechanisms — whether a symmetry breaking, amplification, or propagation process could occur over relevant timescales and using only materials that could feasibly be available prebiotically under early Earth conditions.
Hamazaki H, Hotta K (1979). "Purification and characterization of an α-glucosidase specific for hydroxylysine-linked disaccharide of collagen". J. Biol. Chem. 254 (19): 9682–7. doi:10.1016/S0021-9258(19)83570-6. PMID 385589. Hamazaki H, Hotta K (1980). "Enzymatic hydrolysis of disaccharide unit of collagen. Isolation of 2-O-α-D-glucopyranosyl-O-β-D-galactopyranosyl-hydroxylysine glucohydrolase from rat spleens". Eur. J. Biochem. 111 (2): 587–91. doi:10.1111/j.1432-1033.1980.tb04975.x. PMID 7460918. Sternberg M, Spiro RG (1979). "Studies on the catabolism of the hydroxylysine-linked disaccharide units of basement membranes and collagens. Isolation and characterization of a rat kidney α-glucosidase of high specificity". J. Biol. Chem. 254 (20): 10329–36. doi:10.1016/S0021-9258(19)86713-3. PMID 385599.
However, Smithwick et al.'s study noted that, after further preparation, this irregular surface was simply a layer of sediment with a different color than the rest of the slab. The 'frill' or 'halo' of collagen identified by Feduccia was also determined to be misidentified sediment surrounding one of the specimens. Smithwick et al.'s study concluded by stating that the integument preserved on Sinosauropteryx closely resembled that of birds preserved in the same formation. Purported features of collagen fibers were in fact misidentified shadows formed by scratches or irregular sediment, a misidentification perpetuated by the low quality of early Sinosauropteryx photographs.
The number of 60Fe atoms per unit area found on Earth can be estimated if the typical amount of 60Fe ejected from a supernova is known. This can be done by dividing the surface mass density (Σej) by the atomic mass of 60Fe.
Long Story Short is an American adult animated comedy-drama television series that was created by Raphael Bob-Waksberg and premiered on Netflix on August 22, 2025. Before its premiere, it was renewed for a second season, which is set to premiere in 2026.
Sources: en.wikipedia.org
On 18 September 2026, the United States, Denmark, and Greenland reached an agreement in which the United States would receive the rights to an expanded military footprint in Greenland with greater security control, without, according to the Danish and Greelandic governments, conditionally transferring much military sovereignty of Greenland to the United States. The agreement was signed on 22 September 2026.
Macrophages () are a type of white blood cell of the innate immune system that engulf and digest pathogens, such as cancer cells, microbes, cellular debris and foreign substances, which do not have proteins that are specific to healthy body cells on their surface. This self-protection method can be contrasted with that employed by natural killer cells. This process of engulfment and digestion is called phagocytosis; it acts to defend the host against infection and injury. Macrophages are found in essentially all tissues, where they patrol for potential pathogens by amoeboid movement. They take various forms (with various names) throughout the body (e.g., histiocytes, Kupffer cells, alveolar macrophages, microglia, and others), but all are part of the mononuclear phagocyte system. Besides phagocytosis, they play a critical role in nonspecific defense (innate immunity) and also help initiate specific defense mechanisms (adaptive immunity) by recruiting other immune cells such as lymphocytes. For example, they are important as antigen presenters to T cells. In humans, dysfunctional macrophages cause severe diseases such as chronic granulomatous disease that result in frequent infections. Beyond increasing inflammation and stimulating the immune system, macrophages also play an important anti-inflammatory role and can decrease immune reactions through the release of cytokines. Macrophages that encourage inflammation are called M1 macrophages, whereas those that decrease inflammation and encourage tissue repair are called M2 macrophages.
== Society and culture == In 1966 in the U.S. and Canada, Jerry Lewis and the Muscular Dystrophy Association (MDA) began the annual Labor Day telecast The Jerry Lewis Telethon, significant in raising awareness of muscular dystrophy in North America. Some disability-rights advocates have criticized the telethon for portraying victims of the disease as deserving pity rather than respect. On December 18, 2001, the MD CARE Act was signed into law in the United States. The law amends the Public Health Service Act to provide research for the various muscular dystrophies and established the Muscular Dystrophy Coordinating Committee to help focus research efforts through a coherent research strategy.
In Gibraltar, members of parliament serve in the unicameral Gibraltar Parliament. There are 17 seats in the Parliament, to which candidates are elected by block voting. Each candidate represents the whole of Gibraltar as their constituency.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.